TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3572208
Drug: Labetalol 100
Normalized name: HCTZ 25/LABETALOL 100MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol 100 mg
Study: 17105584
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g alcohol (group 1)
Study: 15336468
Drug: Tramadol/Acetaminophen 75/650
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol/Acetaminophen 75/650 mg (Tr/Ac)
Study: 15336468
Drug: Codeine/Acetaminophen/Ibuprofen 20/500/400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Codeine/Acetaminophen/Ibuprofen 20/500/400 mg (Co/Ac/Ib)
Study: 2502165
Drug: Nalbuphine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalbuphine (15 mg 70 kg-1)
Study: 2502165
Drug: Nalbuphine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalbuphine (30 mg 70 kg-1)
Study: 2502165
Drug: Nalbuphine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalbuphine (60 mg 70 kg-1)
Study: 2502165
Drug: Nalbuphine (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalbuphine (all doses)
Study: 2502165
Drug: Naloxone (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (0.4 mg 70 kg-1)
Study: 12953943
Drug: CPC+ TO
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPC+ TO (clocortolone pivalate cream 0.1% + tacrolimus ointment 0.1%)
Study: 11139095
Drug: Antiarrythmic drugs
Normalized name: ANTIARRHYTHMICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiarrythmic drugs
Study: 11139095
Drug: Various treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various treatment modalities
Study: 9087151
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate aqueous nasal spray 200 micrograms bid
Study: 9087151
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate aqueous nasal spray 200 micrograms bid
Study: 8436162
Drug: Antacid (aluminium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacid (aluminium hydroxide 800 mg and magnesium hydroxide 800 mg), tid, added to a stable regimen of theophylline SR bid for 4 days.
Study: 3963039
Drug: 2 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ml/kg of 100-proof vodka in orange juice
Study: 27186550
Drug: 1000 IU
Normalized name: D 1000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 IU of Vitamin D daily (Group 1)
Study: 27186550
Drug: 30,000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30,000 IU of Vitamin D monthly (Group 2)
Study: 27186550
Drug: 2000 IU
Normalized name: D 2000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2000 IU of Vitamin D daily (Group 3)
Study: 27186550
Drug: 60,000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60,000 IU of Vitamin D monthly (Group 4)
Study: 27186550
Drug: Group 2K
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2K (2000 IU daily and 60,000 IU monthly)
Study: 27186550
Drug: Group 1K
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1K (1000 IU daily and 30,000 IU monthly)
Study: 16634338
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy programme
Study: 10946866
Drug: Ad libitum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad libitum intake after each treatment period
Study: 8610913
Drug: Edrophonium 1
Normalized name: edrophonium 10 mg/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edrophonium 1 mg/kg with atropine 10 micrograms/kg given when NMT of the AP was 1% or 10% of baseline
Study: 3571043
Drug: Gentamicin bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin bolus iv injection (80 mg)
Study: 3571043
Drug: Gentamicin infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin infusion over 15 min (80 mg)
Study: 16901186
Drug: Sertaconazole nail
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertaconazole nail patch (3.63 mg)
Study: 16901186
Drug: Control patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control patch (no antifungal agent)
Study: 12799627
Drug: 5-FU/FA (5-FU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-FU/FA (5-FU 425 mg m(‐2) i.v. and FA 20 mg m(‐2) i.v. bolus days 1‐5 every 28 days for 6 months
Study: 12799627
Drug: PVI 5-FU
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PVI 5-FU (300 mg m(‐2) day for 12 weeks)
Study: 9928753
Drug: felodipine-metoprolol 5/50
Approvals — FDA: no, EMA: no, PMDA: no
Description: felodipine-metoprolol 5/50 mg once daily
Study: 7495045
Drug: benazepril (10-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: benazepril (10-20 mg once a day)
Study: 2312804
Drug: Modified iontophoretic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified iontophoretic method with an anticholinergic agent and aluminum chloride
Study: 648378
Drug: Prednisone (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (15 mg/day)
Study: 648378
Drug: Azathioprine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azathioprine (2 mg/kg daily)
Study: 648378
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of prednisone (10 mg/day) and azathioprine (2 mg/kg daily)
Study: 24742343
Drug: PursuingPleasure (PP)
Normalized name: propoxyphene hydrochloride Oral Capsule [PP-Cap]
Approvals — FDA: no, EMA: no, PMDA: no
Description: PursuingPleasure (PP) - online cognitive behavioral therapy program with mindfulness training and chat groups
Study: 19591723
Drug: Placebo (hand
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (hand cream)
Study: 16490874
Drug: Montelukast sodium
Normalized name: Montelukast Sodium
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Montelukast sodium (10 mg)
Study: 16490874
Drug: Pseudoephedrine hydrochloride
Normalized name: Pseudoephedrine Hydrochloride
DrugBank: Pseudoephedrine (DB00852)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pseudoephedrine hydrochloride (240 mg)
Study: 15575054
Drug: Flecainide or
Normalized name: flecainide Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flecainide or propafenone (self-administered)
Study: 9264305
Drug: Betatolol 0.25%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betatolol 0.25% suspension
Study: 3718378
Drug: Spironolactone, 25
Normalized name: Spironolactone, 25 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone, 25 mg PO QID for 48 h prior to and during exposure
Study: 30400570
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose (1 × 10^10 CFU per day)
Study: 30400570
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose (2.5 × 10^8 CFU per day)
Study: 20858857
Drug: All-trans retinoic
Normalized name: all trans Retinoic acid
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All-trans retinoic acid-based therapy (in 155 patients with M3V)
Study: 20858857
Drug: All-trans retinoic
Normalized name: all trans Retinoic acid
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All-trans retinoic acid-based therapy (in 748 patients with classical M3)
Study: 16389183
Drug: Sequential BCG
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential BCG and electromotive mitomycin
Study: 10355866
Drug: Fluvastatin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin treatment for 12 weeks
Study: 10355866
Drug: Fluvastatin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin treatment after placebo for long-term
Study: 6183898
Drug: Oral D-penicillamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral D-penicillamine
Study: 29782224
Drug: Dupilumab (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dupilumab (300 mg every 2 weeks for 24 weeks)
Study: 24581894
Drug: Shortened form
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shortened form of problem-solving therapy focusing on caregiver burden
Study: 22149151
Drug: Controlled-release aceclofenac
Normalized name: aceclofenac
DrugBank: Aceclofenac (DB06736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Controlled-release aceclofenac 200 mg od (Clanza CR®)
Study: 22149151
Drug: Immediate-release aceclofenac
Normalized name: aceclofenac
DrugBank: Aceclofenac (DB06736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate-release aceclofenac 100 mg bid (Airtal®)
Study: 22149151
Drug: Controlled-release aceclofenac
Normalized name: aceclofenac
DrugBank: Aceclofenac (DB06736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Controlled-release aceclofenac 200 mg od (Clanza CR®) fed state
Study: 22149151
Drug: Controlled-release aceclofenac
Normalized name: aceclofenac
DrugBank: Aceclofenac (DB06736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Controlled-release aceclofenac 200 mg od (Clanza CR®) fasted state
Study: 16039293
Drug: 17beta-estradiol 1mg
Normalized name: Estradiol-17beta
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 17beta-estradiol 1mg daily
Study: 11966505
Drug: Mosapride 5
Normalized name: mosapride 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mosapride 5 mg b.d.
Study: 11966505
Drug: Mosapride 10
Normalized name: mosapride
DrugBank: Mosapride (DB11675)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mosapride 10 mg b.d.
Study: 11966505
Drug: Mosapride 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mosapride 7.5 mg t.d.s.
Study: 8065590
Drug: Leuprolide acetate
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide acetate (3.75 mg/monthly)
Study: 8065590
Drug: Danazol (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danazol (600 mg/daily)
Study: 2967780
Drug: Tizanidine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tizanidine (4 mg three times daily)
Study: 31628887
Drug: Patient counselling
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient counselling covering asthma knowledge, control, adherence to treatment and inhalation techniques
Study: 25300460
Drug: Nilvadipine (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nilvadipine (8 mg overencapsulated, sustained release capsule)
Study: 25300460
Drug: Placebo (matching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (matching overencapsulated sugar pill)
Study: 22791756
Drug: T gel
Normalized name: Joint Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: T gel 10 g + NES gel 8 mg
Study: 22791756
Drug: T gel
Normalized name: Joint Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: T gel 10 g + NES gel 12 mg
Study: 22791756
Drug: T gel
Normalized name: Joint Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: T gel 10 g + NES 0 mg (placebo)
Study: 2519530
Drug: Prednisone (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (60 mg per day, tapered to 20 mg per day)
Study: 2519530
Drug: Cyclosporine (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine (7.5 mg per kilogram of body weight per day)
Study: 2519530
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of cyclosporine and low dose prednisone
Study: 31727538
Drug: Abiraterone acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Abiraterone acetate 1000 mg orally once daily plus prednisone 5 mg orally twice daily until PSA progression followed by enzalutamide 160 mg orally once daily (group A)
Study: 31727538
Drug: Enzalutamide 160
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Enzalutamide 160 mg orally once daily (as second-line therapy after abiraterone)
Study: 31727538
Drug: Abiraterone acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Abiraterone acetate 1000 mg orally once daily plus prednisone 5 mg orally twice daily (as second-line therapy after enzalutamide)
Study: 26254706
Drug: Beta2-microglobulin >1.92
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta2-microglobulin >1.92 mg/L
Study: 26254706
Drug: C-peptide <1.32
Approvals — FDA: no, EMA: no, PMDA: no
Description: C-peptide <1.32 ng/ml
Study: 26254706
Drug: C-peptide <2.22
Approvals — FDA: no, EMA: no, PMDA: no
Description: C-peptide <2.22 ng/ml
Study: 19033149
Drug: Internet-based problem
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based problem solving therapy (PST)
Study: 6363079
Drug: Lidoflazine and
Normalized name: Lidoflazine
DrugBank: Lidoflazine (DB13766)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidoflazine and propranolol combination
Study: 22727431
Drug: Non-ASV treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-ASV treatment
Study: 18076864
Drug: TiF(4) solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: TiF(4) solution applied (ERO+F)
Study: 18076864
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (ERO+no-F)
Study: 11841884
Drug: Verapamil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil infusion at a rate of 1 mg/min to a maximum of 20 mg
Study: 11841884
Drug: Diltiazem infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem infusion at a rate of 2.5 mg/min to a maximum of 50 mg
Study: 7772352
Drug: Macintosh laryngoscope
Approvals — FDA: no, EMA: no, PMDA: no
Description: Macintosh laryngoscope (Group L)
Study: 2286469
Drug: Nitrofurantoin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrofurantoin (200 mg per day for one week)
Study: 323118
Drug: Atropine 2-4
Normalized name: atropine 2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine 2-4 mg/day
Study: 323118
Drug: Cimetidine 1
Normalized name: cimetidine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 1 g/day and Atropine 2-4 mg/day
Study: 31163975
Drug: Syndemic factors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Syndemic factors (e.g., polydrug use, hazardous alcohol consumption, client‐perpetrated violence, depression, and sexually transmitted infections)
Study: 31300264
Drug: Caloric vestibular
Normalized name: Chloric acid
DrugBank: Chloric acid (DB14150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caloric vestibular stimulation (CVS) via a portable device, self-administered twice daily for 8 weeks.
Study: 31300264
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (no specific details provided).
Study: 28961838
Drug: R-CHOP administered
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-CHOP administered every 14 days with CNS prophylaxis (IT methotrexate)
Study: 28961838
Drug: R-CHOP administered
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-CHOP administered every 21 days with CNS prophylaxis (IT methotrexate)
Study: 24932945
Drug: Self-reported drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-reported drug use
Study: 18778385
Drug: Drug Information
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug Information and Advice (Control)
Study: 16914772
Drug: control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: control group (standard treatment alone)
Study: 12809330
Drug: Heptavalent conjugate
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Heptavalent conjugate vaccine
Study: 10894286
Drug: famciclovir 500
Normalized name: famciclovir 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: famciclovir 500 mg twice a day
Study: 10894286
Drug: acyclovir 400
Normalized name: acyclovir 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: acyclovir 400 mg five times a day
Study: 6505269
Drug: High doses
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High doses of alpha 2 Interferon (20 X 10(6) I.U./m2 subcutaneously three times weekly for 3 months)
Study: 6505269
Drug: High doses
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High doses of alpha 2 Interferon (50 X 10(6) I.U./m2 intravenously daily for 5 consecutive days every 4 weeks)
Study: 29945650
Drug: Cognitive Behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behaviour Therapy (CBT) with telephone support
Study: 26756623
Drug: Object-related bilateral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Object-related bilateral symmetrical training with mirror therapy (MT)
Study: 25306688
Drug: Epidural blockade
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural blockade with local anesthetics and small doses of steroids
Study: 12399273
Drug: 1 mmol
Normalized name: monobasic potassium phosphate 1 MMOL/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mmol arginine/kg lean body mass + 25 g glucose
Study: 12399273
Drug: 25 g
Normalized name: AndroGel 1.25 g Packets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 g glucose alone
Study: 24444781
Drug: Medium-dose ASA
Normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-dose ASA
Study: 22531418
Drug: γ-secretase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: γ-secretase inhibitor semagacestat (100 mg)
Study: 22531418
Drug: γ-secretase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: γ-secretase inhibitor semagacestat (140 mg)
Study: 22531418
Drug: γ-secretase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: γ-secretase inhibitor semagacestat (280 mg)
Study: 20805115
Drug: E5555 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: E5555 (50 mg)
Study: 20805115
Drug: E5555 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: E5555 (100 mg)
Study: 20805115
Drug: E5555 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: E5555 (200 mg)
Study: 11881864
Drug: β-adrenergic antagonists
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: β-adrenergic antagonists (β‐AAs)
Study: 11881864
Drug: Acute administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acute administration of β‐AAs
Study: 9792124
Drug: Standard preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard preventive programme (control) comprising selective fissure sealing and application of topical fluorides
Study: 6102940
Drug: Alprazolam (0.5‐3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam (0.5‐3.0 mg)
Study: 6102940
Drug: Diazepam (5‐60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (5‐60 mg)
Study: 29061359
Drug: Root canal
Normalized name: Canal + Gel 10% for Root Canal Preparation Dental Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Root canal treatment
Study: 25534724
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of LFF571 four times daily for 10 days
Study: 23962593
Drug: Overall closed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall closed reduction treatment
Study: 21258836
Drug: Goshajinkigan (GJG)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goshajinkigan (GJG) 7.5 g/day during mFOLFOX6 therapy
Study: 14985685
Drug: DHA group
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA group (n=20) took active foods containing fish oil (3.6 g DHA/week) for 2 months
Study: 9599737
Drug: Enuretic group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enuretic group (treatment)
Study: 143889
Drug: Induced abortion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induced abortion with concurrent tubal ligation (Group 1)
Study: 9389847
Drug: Human albumin
Normalized name: Human albumin
DrugBank: Albumin human (DB00062)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human albumin priming solution
Study: 3316303
Drug: Bendroflumethiazide (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendroflumethiazide (5 mg)
Study: 3316303
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (Bendroflumethiazide + Nifedipine)
Study: 31810865
Drug: Biomarker-guided recommendation
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Biomarker-guided recommendation on antibiotics (n=104)
Study: 31810865
Drug: Routine use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine use of antibiotics (n=106)
Study: 18588355
Drug: NCB-02 (curcumin
Approvals — FDA: no, EMA: no, PMDA: no
Description: NCB-02 (curcumin 150 mg twice daily)
Study: 14622893
Drug: Home-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based intervention consisting of 10 weekly lessons focusing on child health and home safety.
Study: 8846863
Drug: Tamoxifen (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (20 mg twice daily)
Study: 8846863
Drug: Tamoxifen (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (20 mg twice daily) after crossover
Study: 1444318
Drug: MAB-T88 (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAB-T88 (1 mg/kg)
Study: 1444318
Drug: MAB-T88 (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAB-T88 (4 mg/kg)
Study: 1444318
Drug: MAB-T88 (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAB-T88 (8 mg/kg)
Study: 29901441
Drug: XIENCE (durable
Approvals — FDA: no, EMA: no, PMDA: no
Description: XIENCE (durable polymer drug‐eluting stent)
Study: 27082108
Drug: Tamsulosin 0.4
Normalized name: tamsulosin 0.4 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin 0.4 mg daily for a maximum of 12 weeks
Study: 24158940
Drug: DA-6034 10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: DA-6034 10, 20, 50, 100 or 200 mg single dose
Study: 24158940
Drug: DA-6034 40,
Approvals — FDA: no, EMA: no, PMDA: no
Description: DA-6034 40, 100 or 200 mg/day multiple doses for 7 days
Study: 24158940
Drug: Placebo (not
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (not specified dosage)
Study: 16601828
Drug: 90 microg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 microg/kg rFVIIa (3 doses at 3-hour intervals)
Study: 14585671
Drug: HA/Vi vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: HA/Vi vaccine
Study: 14585671
Drug: Avaxim vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avaxim vaccine
Study: 8624269
Drug: Pamidronate 120
Normalized name: Pamidronate
DrugBank: Pamidronic acid (DB00282)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pamidronate 120 mg infusion
Study: 6387529
Drug: Diazepam (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (10 mg single dose and 30 mg/day for 2 weeks)